Exercise in Air Pollution and Lung Health in Asthmatics

NCT02252302 | Completed

• 1 other identifier: H13-01079
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

When exposed to air pollution, the asthma symptoms are aggravated and lung function is impaired. Due to high breathing rates and volumes, physically active individuals are at particular risk of lung health impairment due to the high breathing rates and volumes. Greater doses of air pollutants reach deeper areas in the lungs where they can trigger asthma-symptoms. When treating these symptoms with inhaled beta-2-agonists the airways widen even more, allowing the air pollutants to reach even deeper areas of the lung. With this study the investigators investigate how inhaled beta-2-agonists affect athletic capacity and lung health in physically active asthmatics.

Conditions

Exercise-induced Bronchoconstriction; Air Pollution

Keywords

Exercise-induced bronchoconstriction; Air pollution; Exercise; Inhaled beta-2-agonist; Cognitive Function

Outcome Measures

Primary Outcomes (1)

• Change in rating of perceived exertion for breathing, dyspnea

  Difference in perceived dyspnea between salbutamol and placebo exposure as well as polluted air and filtered air. Dyspnea ratings will be collected every 2.5min for a duration of 45min during the exercise test.

Secondary Outcomes (1)

• Change in work of breathing (WOB) between filtered air and polluted air

  work of breathing will be assessed every 2.5min for a time period of 45min during the exercise bout

Other Outcomes (3)

• Change in spirometry (FEV1 and FVC) between filtered air and polluted air

  Spirometry will be assessed at baseline and 45min after the start of the exercise bout.

• Change in cognitive function

  Cognitive function will be assessed at baseline (prior to entering the air pollution chamber) and 45 min after the start of the exercise intervention.

• Retinal Imaging

  The retina will be imaged at baseline (prior to entering the air pollution chamber) and 20 min after the completion of the exercise intervention.

Study Arms (8)

Resting in diesel exhaust following salbutamol inhalation

ACTIVE COMPARATOR

Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.

Other: Rest (Sitting on chair); Drug: Salbutamol inhalation; Other: Diesel Exhaust Exposure

Resting in diesel exhaust following placebo inhalation

PLACEBO COMPARATOR

Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.

Other: Rest (Sitting on chair); Drug: Placebo inhalation; Other: Diesel Exhaust Exposure

Cycling in diesel exhaust following salbutamol inhalation

ACTIVE COMPARATOR

Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.

Other: Cycling exercise; Drug: Salbutamol inhalation; Other: Diesel Exhaust Exposure

Cycling in diesel exhaust following placebo inhalation

PLACEBO COMPARATOR

Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo

Other: Cycling exercise; Drug: Placebo inhalation; Other: Diesel Exhaust Exposure

Resting in filtered air following salbutamol inhalation

SHAM COMPARATOR

Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.

Other: Rest (Sitting on chair); Other: Filtered air

Resting in filtered air following placebo inhalation

PLACEBO COMPARATOR

Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.

Other: Rest (Sitting on chair); Other: Filtered air

Cycling in filtered air following salbutamol inhalation

SHAM COMPARATOR

Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.

Other: Cycling exercise; Drug: Salbutamol inhalation; Other: Filtered air

Cycling in filtered air following placebo inhalation

PLACEBO COMPARATOR

Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo

Other: Cycling exercise; Drug: Placebo inhalation; Other: Filtered air

Interventions

Rest (Sitting on chair) OTHER

Study participants will sit on a chair for 60min. This is to simulate physical resting condition.

Resting in diesel exhaust following placebo inhalation; Resting in diesel exhaust following salbutamol inhalation; Resting in filtered air following placebo inhalation; Resting in filtered air following salbutamol inhalation

Cycling exercise OTHER

Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.

Cycling in diesel exhaust following placebo inhalation; Cycling in diesel exhaust following salbutamol inhalation; Cycling in filtered air following placebo inhalation; Cycling in filtered air following salbutamol inhalation

Salbutamol inhalation DRUG

Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.

Cycling in diesel exhaust following salbutamol inhalation; Cycling in filtered air following salbutamol inhalation; Resting in diesel exhaust following salbutamol inhalation

Placebo inhalation DRUG

Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber

Cycling in diesel exhaust following placebo inhalation; Cycling in filtered air following placebo inhalation; Resting in diesel exhaust following placebo inhalation

Diesel Exhaust Exposure OTHER

Participants will be exposed to PM2.5 of 300 μg/m3

Cycling in diesel exhaust following placebo inhalation; Cycling in diesel exhaust following salbutamol inhalation; Resting in diesel exhaust following placebo inhalation; Resting in diesel exhaust following salbutamol inhalation

Filtered air OTHER

Participants will be breathing filtered air

Cycling in filtered air following placebo inhalation; Cycling in filtered air following salbutamol inhalation; Resting in filtered air following placebo inhalation; Resting in filtered air following salbutamol inhalation

Eligibility Criteria

• Age: 19 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• mild-moderate asthmatics with controlled treatment (definition of "mild": percent fall index at eucapnic voluntary hyperpnea (EVH) test on screening day between 10-15%; "moderate": percent fall index at EVH test on screening day between 15 - 20%).
• men and non-pregnant women

You may not qualify if:

• any history of uncontrolled respiratory or cardiac disease
• pregnancy
• allergic reactions to lidocaine and salbutamol
• any recent infections or orthopaedic nasal issues/injuries that may interfere with the insertion of the catheter needed to assess expiratory flow limitation or work of breathing
• claustrophobia in small rooms, comparable to the air pollution chamber used for this study.
• English as a second language (ESL) - participants who are not able to understand the risk that may be associated with the participation in this study due to language difficulties after following the University of British Clinical Research Ethics Board Guidance Notes 13.2.1. (ESL participants will be given a consent form in the most appropriate language or an appropriate translator will be present during the initial consent process).

Sponsors & Collaborators

• University of British Columbia: lead
• Canadian Academy of Sport and Exercise Medicine (CASEM): collaborator
• Natural Sciences and Engineering Research Council, Canada: collaborator
• Fraser Basin Council: collaborator

Study Sites (1)

University of British Columbia, Environmental Physiology Laboratory

Vancouver, British Columbia, V6T 1Z1, Canada

Location

MeSH Terms

Conditions

Motor Activity

Interventions

RE1-silencing transcription factor

Condition Hierarchy (Ancestors)

Behavior

Study Officials

• Michael S Koehle, MD, PhD

  University of British Columbia

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigaor

Study Record Dates

• First Submitted: September 16, 2014
• First Posted: September 30, 2014
• Study Start: May 1, 2015
• Primary Completion: August 1, 2016
• Study Completion: May 1, 2021
• Last Updated: September 30, 2021

Record last verified: 2021-09

Locations

CA (1)